Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter H. Nielsen MBA | Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer | 696.24k | -- | 1949 |
| Mr. Douglas P. Morris | Co-Founder, Director of Investor Relations, Secretary & Director | 73.74k | -- | 1956 |
| Mr. Michael Hickey M.B.A. | VP of Clinical Operations | -- | -- | -- |
| Mr. Anthony Price | Senior Vice President of Finance, Accounting & Administration | -- | -- | -- |
| Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D. | Senior Vice President of Research, Development & Clinical Design | -- | -- | -- |
Bio-Path Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
Corporate Governance
Upcoming Events
March 6, 2025 at 1:30 PM UTC - March 10, 2025 at 1:30 PM UTC
Bio-Path Holdings, Inc. Earnings Date
Recent Events
October 21, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission